Denali Therapeutics (NASDAQ:DNLI) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

DNLI has been the topic of a number of other reports. Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a report on Monday, June 22nd. Morgan Stanley lifted their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. B. Riley Financial increased their price objective on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Wedbush reissued an “outperform” rating and issued a $26.00 target price on shares of Denali Therapeutics in a report on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Denali Therapeutics Trading Up 4.2%

NASDAQ:DNLI opened at $19.45 on Friday. The company has a market cap of $3.11 billion, a PE ratio of -6.85 and a beta of 1.02. The business’s 50 day moving average is $22.40 and its two-hundred day moving average is $21.83. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 52 week low of $13.75 and a 52 week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the company posted ($0.72) earnings per share. On average, analysts predict that Denali Therapeutics will post -2.67 EPS for the current year.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Denali Therapeutics in the second quarter worth $26,000. Global Retirement Partners LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $28,000. Nykredit A S acquired a new stake in Denali Therapeutics in the second quarter worth about $38,000. Allworth Financial LP acquired a new stake in Denali Therapeutics in the second quarter worth about $47,000. Finally, GAMMA Investing LLC grew its position in Denali Therapeutics by 44.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock valued at $46,000 after buying an additional 687 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders.

Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain.